Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome: early-phase trial registry
1 of 2 indexed Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome: 2 US clinical trials tracked, 1 recruiting.
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ionis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition methyl-cpg-binding-protein-2-mecp2-duplication-syndrome
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Ionis Pharmaceuticals
NCT06430385
Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals
NCT06014541
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ionis Pharmaceuticals sponsors the most Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome trials on record, review their full trial history before evaluating a specific study. See Ionis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome condition card totals 2 registered trials; most-linked intervention ION440; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.